Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review by Anna C. Pavlick, DO, MBA, of New York University Perlmutter Cancer Center, and colleagues, who noted that while research in this area in rapidly progressing, the answer to this important...

Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review in ASCO Educational Book by Anna C. Pavlick, DO, MBA, and colleagues at New York University Perlmutter Cancer Center, who noted that while research in this area is rapidly progressing, the...